Ji Jingbin, Zhang Chenyu, Peng Lei, Jiao Wenjie
Department of Thoracic Surgery, Affiliated Hospital of Qingdao University, Qingdao 266071, China.
Zhongguo Fei Ai Za Zhi. 2022 Feb 20;25(2):92-101. doi: 10.3779/j.issn.1009-3419.2022.101.01.
The emergence of immune checkpoint inhibitors (ICIs) has dramatically changed the therapeutic outlook for patients with non-small cell lung cancer (NSCLC). Preoperative neoadjuvant immunotherapy has been paid more and more attention as an effective and safe treatment. Neoadjuvant immune therapy, however, the relevant research started late, relatively few research results and mainly focused on the small sample size of phase I and II studies, treatment itself exists many places it is not clear, also in benefit population screening, the respect such as the choice of treatment and curative effect prediction has not yet reached broad consensus. This paper reviews the important studies and recent achievements related to neoadjuvant immunotherapy, aiming to comprehensively discuss the procedures and existing problems of this kind of therapy from three aspects of beneficiary groups, treatment cycle and efficacy prediction. .
免疫检查点抑制剂（ICI）的出现极大地改变了非小细胞肺癌（NSCLC）患者的治疗前景。术前新辅助免疫治疗作为一种有效且安全的治疗方法越来越受到关注。然而，新辅助免疫治疗相关研究起步较晚，研究成果相对较少，且主要集中在样本量较小的I期和II期研究，治疗本身存在许多尚不清楚的地方，在获益人群筛选、治疗选择及疗效预测等方面也尚未达成广泛共识。本文综述了与新辅助免疫治疗相关的重要研究及最新成果，旨在从受益人群、治疗周期和疗效预测三个方面全面探讨此类治疗的流程及存在的问题。
